Life Sciences Tools & Reagents / Diagnostics & Research
Strategic Profile
The company monetizes its technology primarily via sales through its global distribution network and licensing. As of August 20, 2025, Enzo Biochem was taken private by Battery Ventures. The company serves academic researchers, clinical researchers, biotechnology and pharmaceutical companies, and diagnostic manufacturers.
Cyborg Score Rationale
The company has a market capitalization of approximately $36.59 million and revenues of $27.47 million. The company faced significant headwinds including delisting from NYSE in 2025 and subsequent take-private transaction, alongside declining earnings trajectory.
Top Insights
Underwent strategic alternatives review in April 2025 and was taken private by Battery Ventures in August 2025, removing public market pressures
Substantial micro-cap with minimal market capitalization (~$36M) and modest revenue (~$27M), indicating limited scale
Operates in mission-critical research tools space serving biotech, pharma, and academic institutions with defensible IP
Historical challenges include earnings decline, NYSE delisting, and data privacy settlement ($4.5M) in 2024
Named Competitors
Life Science Tools & Reagents — Diversified life sciences and diagnostics leader
Research Reagents — Life sciences research and clinical diagnostics products
Antibodies & Detection Tools — Research-grade antibodies and assays